Treatment of Seasonal Allergic Conjunctivitis

Allergic conjunctivitis affects approximately 15% of the global population and has a higher prevalence of about 40% in industrialized countries such as the United States. Seasonal allergy sufferers present with a variety of signs and symptoms, but patients frequently report that ocular allergy symptoms are the most bothersome. Many topical ocular prescription therapies are available and are increasingly prescribed due to patient demand for effective resolution of ocular allergy symptoms. Corticosteroidbased therapies such as loteprednol etabonate 0.2%, which act at a high level on the inflammatory cascade and thus broadly inhibit many inflammatory mediators, offer temporary relief of the signs and symptoms associated with seasonal allergic conjunctivitis.